Saniona initiates preparation of Phase 2a study
Saniona, a leading biotech company within ion-channel research, initiates a Phase 2a proof of concept study for the combination of Tesofensine and Metoprolol for treatment of type 2 diabetes in 2016. The company is now initiating the manufacturing of study materials for the trial. In addition Saniona, announce that it has received notice of allowance in the U.S. covering the combination.“This is another important step for us as we are transforming from pre-clinical stage to a company with clinical activities”, says Jørgen Drejer, CEO of Saniona. Saniona intends to initiate a Phase 2a